Cargando…

Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination

We report the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receiving the coronavirus disease 2019 (COVID-19) vaccine BNT162b (Pfizer–BioNTech). A 37-year-old Japanese woman had been taking propylthiouracil for Graves’ disease. She had e...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuda, Saki, Hirooka, Yasuaki, Sugiyama, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402331/
https://www.ncbi.nlm.nih.gov/pubmed/34451967
http://dx.doi.org/10.3390/vaccines9080842
_version_ 1783745763848749056
author Okuda, Saki
Hirooka, Yasuaki
Sugiyama, Masafumi
author_facet Okuda, Saki
Hirooka, Yasuaki
Sugiyama, Masafumi
author_sort Okuda, Saki
collection PubMed
description We report the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receiving the coronavirus disease 2019 (COVID-19) vaccine BNT162b (Pfizer–BioNTech). A 37-year-old Japanese woman had been taking propylthiouracil for Graves’ disease. She had erythema on her forearm on the 12th day after receiving the first dose of the vaccine, fever on the 13th day, and redness and swelling of her left auricle on the 25th day. Her serum myeloperoxidase-ANCA and proteinase 3-ANCA levels, which were negative before the Graves’ disease treatment, were elevated. She had unilateral auricular symptoms but no other typical relapsing polychondritis findings. She was diagnosed with propylthiouracil-induced AAV. She was treated with oral glucocorticoids, and her symptoms improved. Propylthiouracil is considered to be the main cause of the onset of AAV in this case, but it cannot be ruled out that BNT162b may have had some effect on the onset of the disease. Although the development of propylthiouracil-induced AAV in this case may have been incidental and unrelated to the vaccination, this report provides important data for evaluating the safety of the vaccine.
format Online
Article
Text
id pubmed-8402331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84023312021-08-29 Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination Okuda, Saki Hirooka, Yasuaki Sugiyama, Masafumi Vaccines (Basel) Communication We report the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receiving the coronavirus disease 2019 (COVID-19) vaccine BNT162b (Pfizer–BioNTech). A 37-year-old Japanese woman had been taking propylthiouracil for Graves’ disease. She had erythema on her forearm on the 12th day after receiving the first dose of the vaccine, fever on the 13th day, and redness and swelling of her left auricle on the 25th day. Her serum myeloperoxidase-ANCA and proteinase 3-ANCA levels, which were negative before the Graves’ disease treatment, were elevated. She had unilateral auricular symptoms but no other typical relapsing polychondritis findings. She was diagnosed with propylthiouracil-induced AAV. She was treated with oral glucocorticoids, and her symptoms improved. Propylthiouracil is considered to be the main cause of the onset of AAV in this case, but it cannot be ruled out that BNT162b may have had some effect on the onset of the disease. Although the development of propylthiouracil-induced AAV in this case may have been incidental and unrelated to the vaccination, this report provides important data for evaluating the safety of the vaccine. MDPI 2021-07-31 /pmc/articles/PMC8402331/ /pubmed/34451967 http://dx.doi.org/10.3390/vaccines9080842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Okuda, Saki
Hirooka, Yasuaki
Sugiyama, Masafumi
Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title_full Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title_fullStr Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title_full_unstemmed Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title_short Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
title_sort propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis after covid-19 vaccination
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402331/
https://www.ncbi.nlm.nih.gov/pubmed/34451967
http://dx.doi.org/10.3390/vaccines9080842
work_keys_str_mv AT okudasaki propylthiouracilinducedantineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccination
AT hirookayasuaki propylthiouracilinducedantineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccination
AT sugiyamamasafumi propylthiouracilinducedantineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccination